Publications scientifiques Bordet

Publications scientifiques Bordet

RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.

Jacobs F, D'Amico S, Ferraro E, Agostinetto E, Tondini C, Gaudio M, Benvenuti C, Gerosa R, Saltalamacchia G, Zazzetti E, Di Rienzo R, Buonaiuto R, Martorana F, Chirco A, De Sanctis R, Della Porta MG, Santoro A, Vigneri P, Arpino MG, Giuliano M, Fornier M, de Azambuja E, Zambelli A

RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Lei M, Overman MJ, Yao J, André T, Lonardi S, Lenz HJ, Aglietta M, Gelsomino F, McDermott R, Wong KYM, Morse MA, Van Cutsem E, Hendlisz A, Cardin DB, Neyns B, Hill A, Krishnamurthy A, Chen F, Kochuparambil S, Jenq RR, Abdullaev S, He B, Novosiadly R, Kopetz S

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Temporal trends and clinical determinants of urinary diversion after radical cystectomy.

Pellegrino F, de Angelis M, Scilipoti P, Longoni M, Subiela JD, Contieri R, Afferi L, Zamboni S, Suardi N, Musi G, Luzzago S, D'Andrea D, Laukhtina E, Soria F, Gontero P, Del Giudice F, Fallara G, Roupret M, Grobet-Jeandin E, Baudewyns A, Tanaka H, Matsumoto S, Fujii Y, Proietti F, Simone G, Schulz GB, Pyrgidis N, Ploussard G, Antonelli A, Bertolo R, Roumiguie M, Bajeot AS, Resca S, Beatrici E, Lambert E, Mottrie A, Mir MC, Umari P, Teoh J, Wong C, Mertens LS, Pichler R, Mori K, Ślusarczyk A, Poyet C, Albisinni S, Aziz A, Volpe A, Shariat S, Pradere B, Karakiewicz P, Necchi A, Ferro M, Montorsi F, Briganti A, Moschini M

Temporal trends and clinical determinants of urinary diversion after radical cystectomy.

Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.

Kwong JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, Kim K, Ringa M, Feifer A, Lajkosz K, Wettstein MS, Chan A, Lee T, Nguyen M, Kassouf W, Black PC, Breau RH, Lodde M, Fairey A, Lattouf JB, Jeldres C, Rendon R, Alimohamed N, Fleshner NE, Diamand R, Gontero P, Sylvester RJ, van Rhijn BWG, Kamat AM, Johnson AEW, Zlotta AR, Kulkarni GS

Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.
Erasme hospital

Hôpital Erasme

Consultez toutes les publications scientifiques d'Erasmus

Publications scientifiques d'Erasmus
Huderf hospital

Hôpital pédiatrique Reine Fabiola

Consultez toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola

Publications scientifiques de l'Hôpital pour enfants Reine Fabiola
Bordet hospital

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet

Publications scientifiques de Jules Bordet